- Food and Drug Administration. Licensed product information. Available at http://www.fda.gov/cber/efoi/approve.htm; accessed April 2002.
- Adamson JW, Longo DL. Anemia and polycythemia. In Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL eds. Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill, 2001: 348–354.
- Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91: 1616–1634.
- National Kidney Foundation. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37 (1 Suppl 1): S182–S238.
- Skorecki K, Green J, Brenner BM. Chronic renal failure. In Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL eds. Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill, 2001: 1551–1562.
- Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84 (Suppl 1): 3–10.
- Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20: 375–381.
- Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10: 2392–2395.
- Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60: 741–747.
- Amgen, Inc. Aranesp physician package insert. Thousand Oaks, Calif: Amgen, Inc, September 14, 2001.
- Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001;84 (Suppl 1): 11–16.
- Ortho Biotech, Inc. Procrit prescribing information. Raritan, NJ: Ortho Biotech, Inc, March 2000 (rev).
- Amgen, Inc. Epogen prescribing information. Thousand Oaks, Calif: Amgen, Inc, July 26, 1999.
- Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or every other week [abstract]. J Am Soc Nephrol 1999;10: 270A.
- Graf H, Lacombe JL, Braun I, Gomes da Costa AA. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin when administered at a reduced dose frequency compared with recombinant human erythropoietin in dialysis patients [abstract]. J Am Soc Nephrol 2000;11: A1317.
- Tseng L, Schuller J, Mercer J Colowick A. The pharmacokinetics of Aranesp in oncology patients undergoing multicycle chemotherapy [abstract]. Blood 2000;96 (11): Abstract 4379.
- Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Am J Kidney Dis 1996;28: 535–540.
- Hedenus M, Hansen S, Dewey C, Watson D, Colowick A, Osterborg A. A randomized, blinded, placebo-controlled, phase II, dose finding study of Aranesp in patients with lymphoproliferative malignancies [abstract]. Blood 2000;96 (11): Abstract 4371.
- Glaspy J, Tchekmedyian S, Jadeja J, Richards D, The ARANESP Study 980290 Study Group, O'Byrne J, Armstrong S, Colowick A. Randomized, active-controlled, phase I/II, dose-escalation study of Aranesp in solid tumor patients [abstract]. Blood 2000;96 (11): Abstract 1278.
- Egrie JC, Dwyer E, Lykos M, Hitz A, Browne JK. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biologic activity than recombinant human erythropoietin (rHuEPO) [abstract]. Blood 1997;77 (11): Abstract 243.
- Locatelli F, Olivares J, Walker R, Wilkie M, The European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO) [abstract]. J Am Soc Nephrol 2000;11: A1486.
- Coyne DW, Ling BN, Toto R, McDermott-Vitak AD. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant human erythropoietin [abstract]. J Am Soc Nephrol 2000;11: A1380.
- Kotasek D, Berg R, Poulsen E, Colowick A. Randomized, double-blind, placebo controlled phase I/II dose finding study of Aranesp administered once every three weeks in solid tumor patients [abstract]. Blood 2000;96 (11): Abstract 1268.
- Macdougall IC. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia [abstract]. J Am Soc Nephrol 1998;9 (Suppl): A1317.
- Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick AB. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001;84 (Suppl 1): 17–23.
- Smith RE Jr, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdoch M, Rarick M, Saven A, Colowick AB, Fleishman A, Gayko U, Glaspy J. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001;84 (Suppl 1): 24–30.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 15, 2002 - Issue 3